Research progress on copy number alterations in pediatric B-cell acute lymphoblastic leukemia.
10.7499/j.issn.1008-8830.2501007
- Author:
Xi-Yuan XU
1
;
Qun HU
1
Author Information
1. Department of Pediatric Hematology and Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Publication Type:English Abstract
- Keywords:
Acute lymphoblastic leukemia;
Child;
Copy number alteration;
Prognosis;
Treatment
- MeSH:
Humans;
DNA Copy Number Variations;
Child;
PAX5 Transcription Factor/genetics*;
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Cyclin-Dependent Kinase Inhibitor p15/genetics*;
Ikaros Transcription Factor/genetics*;
Precursor Cell Lymphoblastic Leukemia-Lymphoma/genetics*;
Gene Deletion;
Cyclin-Dependent Kinase Inhibitor p16/genetics*;
Prognosis
- From:
Chinese Journal of Contemporary Pediatrics
2025;27(6):746-752
- CountryChina
- Language:Chinese
-
Abstract:
Copy number alteration (CNA) is a significant genetic change in pediatric B-cell acute lymphoblastic leukemia (B-ALL), with CDKN2A/B deletions, PAX5 deletions, and IKZF1 deletions being the most common. Recent studies have increasingly highlighted the potential prognostic significance of these gene deletions and multiple co-deletions in pediatric B-ALL. This paper reviews the main detection methods for CNA, as well as the prognostic characteristics and treatment approaches for common CNA in pediatric B-ALL.
